Characterization of cannabinoid-1 receptors in the locus coeruleus: Relationship with mu-opioid receptors

Brain Research

Volumn 1312, Issue , 2010, Pages 18-31

  Scavone, Jillian L ^a   Mackie, Ken ^b   Van Bockstaele, Elisabeth J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Cannabinoid receptor localization; Cannabinoid opioid interaction; Electron microscopy; Locus coeruleus; Noradrenergic neuron; Opioid receptor

Indexed keywords

CANNABINOID 1 RECEPTOR; ENZYME ANTIBODY; MU OPIATE RECEPTOR; PEROXIDASE; RECEPTOR ANTIBODY; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; GLIA; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGOLD LABELING; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; KNOCKOUT MOUSE; LOCUS CERULEUS; MALE; MOUSE; NERVE ENDING; NONHUMAN; NONMYELINATED NERVE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; LOCUS COERULEUS; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, IMMUNOELECTRON; NEURONS; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; TYROSINE 3-MONOOXYGENASE;

EID: 73649118803     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.023     Document Type: Article

References (73)

1. Arvidsson U., Riedl M., Chakrabarti S., Lee J.H., Nakano A.H., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., and Elde R. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15 (1995) 3328-3341
2. Aston-Jones G., Astier B., and Ennis M. Inhibition of noradrenergic locus coeruleus neurons by C1 adrenergic cells in the rostral ventral medulla. Neuroscience 48 (1992) 371-381
3. Aston-Jones G., Rajkowski J., Kubiak P., Valentino R.J., and Shipley M.T. Role of the locus coeruleus in emotional activation. Prog. Brain Res. 107 (1996) 379-402
4. Aston-Jones G., Chen S., Zhu Y., and Oshinsky M.L. A neural circuit for circadian regulation of arousal. Nat. Neurosci. 4 (2001) 732-738
5. Aston-Jones G., Zhu Y., and Card J.P. Numerous GABAergic afferents to locus ceruleus in the pericerulear dendritic zone: possible interneuronal pool. J. Neurosci. 24 (2004) 2313-2321
6. Aston-Jones G., and Kalivas P.W. Brain norepinephrine rediscovered in addiction research. Biol. Psychiatry 63 (2008) 1005-1006
7. Bacci A., Huguenard J.R., and Prince D.A. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 431 (2004) 312-316
8. Carrasco G.A., and Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463 (2003) 235-272
9. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., and Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. N. Y. Acad. Sci. 654 (1992) 33-51
10. Cichewicz D.L., Martin Z.L., Smith F.L., and Welch S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. 289 (1999) 859-867
11. Corchero J., Avila M.A., Fuentes J.A., and Manzanares J. delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci. 61 (1997) PL39-PL43
12. Corchero J., Fuentes J.A., and Manzanares J. Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat. J. Psychopharmacol. 16 (2002) 283-289
13. Corchero J., Manzanares J., and Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 16 (2004) 159-172
14. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci. 78 (2006) 549-563
15. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., and Hamon M. International Union of Pharmacology: XII. Classification of opioid receptors. Pharmacol. Rev. 48 (1996) 567-592
16. Dunn A.J., Swiergiel A.H., and Palamarchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann. N. Y. Acad. Sci. 1018 (2004) 25-34
17. Espana R.A., and Berridge C.W. Organization of noradrenergic efferents to arousal-related basal forebrain structures. J. Comp. Neurol. 496 (2006) 668-683
18. Harburg G.C., Hall F.S., Harrist A.V., Sora I., Uhl G.R., and Eisch A.J. Knockout of the mu opioid receptor enhances the survival of adult-generated hippocampal granule cell neurons. Neuroscience 144 (2006) 77-87
19. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
20. Hohmann A.G., Briley E.M., and Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822 (1999) 17-25
21. Hojo M., Sudo Y., Ando Y., Minami K., Takada M., Matsubara T., Kanaide M., Taniyama K., Sumikawa K., and Uezono Y. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J. Pharmacol. Sci. 108 (2008) 308-319
22. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
23. Jahn R., Schiebler W., Ouimet C., and Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4137-4141
24. Koob G.F., Maldonado R., and Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci. 15 (1992) 186-191
25. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
26. Lichtman A.H., Sheikh S.M., Loh H.H., and Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 298 (2001) 1007-1014
27. Lu X.R., Ong W.Y., and Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in monkey basal forebrain. J. Neurocytol. 28 (1999) 1045-1051
28. Maldonado R., and Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur. Neuropsychopharmacol. 13 (2003) 401-410
29. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res. Mol. Brain Res. 55 (1998) 126-132
30. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-294
31. Massi P., Vaccani A., Rubino T., and Parolaro D. Cannabinoids and opioids share cAMP pathway in rat splenocytes. J. Neuroimmunol. 145 (2003) 46-54
32. Mendiguren A., and Pineda J. Cannabinoids enhance N-methyl-d-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neurosci. Lett. 363 (2004) 1-5
33. Mendiguren A., and Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur. J. Pharmacol. 534 (2006) 83-88
34. Mendiguren A., and Pineda J. CB(1) cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Neuropharmacology 52 2 (2006) 617-625
35. Mendiguren A., and Pineda J. CB(1) cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Neuropharmacology 52 (2007) 617-625
36. Muntoni A.L., Pillolla G., Melis M., Perra S., Gessa G.L., and Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur. J. Neurosci. 23 (2006) 2385-2394
37. Nestler E.J. Cellular responses to chronic treatment with drugs of abuse. Crit. Rev. Neurobiol. 7 (1993) 23-39
38. Nestler E.J., Alreja M., and Aghajanian G.K. Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res. Bull. 35 (1994) 521-528
39. Nestler E.J., Alreja M., and Aghajanian G.K. Molecular control of locus coeruleus neurotransmission. Biol. Psychiatry 46 (1999) 1131-1139
40. Ong W.Y., and Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. J. Neurocytol. 28 (1999) 39-45
41. Oropeza V.C., Page M.E., and Van Bockstaele E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 1046 (2005) 45-54
42. Oropeza V.C., Mackie K., and Van Bockstaele E.J. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res. 1127 (2007) 36-44
43. Page M.E., Oropeza V.C., Sparks S.E., Qian Y., Menko A.S., and Van Bockstaele E.J. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol. Biochem. Behav. 86 (2007) 162-168
44. Page M.E., Oropeza V.C., and Van Bockstaele E.J. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci. Lett. 431 (2008) 1-5
45. Paldy E., Bereczki E., Santha M., Wenger T., Borsodi A., Zimmer A., and Benyhe S. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem. Int. 53 (2008) 309-316
46. Pasternak G.W. Molecular biology of opioid analgesia. J. Pain Symptom Manage 29 (2005) S2-S9
47. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
48. Peters A., Palay S., and Webster H. The Fine Structure of the Nervous System (1991), Oxford University Press, New York
49. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., and MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
50. Rasmussen K., and Aghajanian G.K. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res. 505 (1989) 346-350
51. Rasmussen K., Beitner-Johnson D.B., Krystal J.H., Aghajanian G.K., and Nestler E.J. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10 (1990) 2308-2317
52. Reyes B.A., Glaser J.D., and Van Bockstaele E.J. Ultrastructural evidence for co-localization of corticotropin-releasing factor receptor and mu-opioid receptor in the rat nucleus locus coeruleus. Neurosci. Lett. 413 (2007) 216-221
53. Rios C., Gomes I., and Devi L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 148 (2006) 387-395
54. Rodriguez J.J., Mackie K., and Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate-putamen nucleus. J. Neurosci. 21 (2001) 823-833
55. Rozenfeld R., and Devi L.A. Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. Faseb J. 22 (2008) 2311-2322
56. Rubino T., Massi P., Vigano D., Fuzio D., and Parolaro D. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci. 66 (2000) 2213-2219
57. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., and Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 12 (2001) 3689-3692
58. Schoffelmeer A.N., Hogenboom F., Wardeh G., and De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51 (2006) 773-781
59. Smith P.A., Selley D.E., Sim-Selley L.J., and Welch S.P. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur. J. Pharmacol. 571 (2007) 129-137
60. Szabo B., and Schlicker E. Effects of cannabinoids on neurotransmission. Handb. Exp. Pharmacol. (2005) 327-365
61. Tham S.M., Angus J.A., Tudor E.M., and Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 144 (2005) 875-884
62. Valentino R., and Aston-Jones G. Physiological and anatomical determinants of locus coeruleus discharge: Behavioral and clinical implications. In: Kupfer D., and Bloom F.E. (Eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press (1995), Raven Press 373-386
63. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., and Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 13 (2001) 1816-1824
64. Van Bockstaele E.J., and Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J. Comp. Neurol. 334 (1993) 603-617
65. Van Bockstaele E.J., Colago E.E., Cheng P., Moriwaki A., Uhl G.R., and Pickel V.M. Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. J. Neurosci. 16 (1996) 5037-5048
66. Van Bockstaele E.J., Peoples J., Menko A.S., McHugh K., and Drolet G. Decreases in endogenous opioid peptides in the rat medullo-coerulear pathway after chronic morphine treatment. J. Neurosci. 20 (2000) 8659-8666
67. Van Bockstaele E.J., and Commons K.G. Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience 108 (2001) 467-477
68. Van Bockstaele E.J., Menko A.S., and Drolet G. Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure. Mol. Neurobiol. 23 (2001) 155-171
69. Vigano D., Rubino T., and Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav. 81 (2005) 360-368
70. Wang H.Y., and Burns L.H. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J. Neurobiol. 66 (2006) 1302-1310
71. Weinshenker D., and Schroeder J.P. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32 (2007) 1433-1451
72. Wiedenmann B., and Franke W.W. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 41 (1985) 1017-1028
73. Wilson A.R., Maher L., and Morgan M.M. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 55 (2008) 1219-1225